Lyophilization questions answered in real time
Two free webinars - 'Lyophilizer Sublimation and Heat Transfer Modelling' and 'The Freezing Stage in Freeze Drying: Fundamental Concepts 2.0' - delivered by industry experts.
SP Scientific has announced its Fall 2017 program of LyoLearn webinars.
The LyoLearn program of free educational webinars, delivered by industry experts, are devoted to lyophilization, freeze-drying and related topics. Attendees to each of the live sessions are encouraged to ask questions of the presenter and get their answers in real time.
On 26 September 2017 at 9:00 and 13:00 Eastern Time, Timothy R. McCoy of Genzyme will present 'Lyophilizer Sublimation and Heat Transfer Modelling' an informative webinar covering the basic principles around heat and mass transfer related to freeze drying. In addition, the presenter will describe an industry case study at lab and manufacturing scale, demonstrating the approach and application of the model to scale up.
The Freezing Stage in Freeze Drying: Fundamental Concepts 2.0 a webinar presentation will stream on 25 October 2017 at 10:00 and 14:00 Eastern Time. Presented by Dr Margit Gieseler of GILYOS, this webinar aims to provide an update on the current scientific state, covering both the basic principles of freezing in a freeze-drying cycle, as well as the recent developments with regard to control of the freezing stage.
LyoLearn webinars follow a 45-minute format for the presentations with a Q&A session immediately afterwards.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.